<DOC>
	<DOCNO>NCT00250419</DOCNO>
	<brief_summary>To determine safety/tolerability , immunogenicity experimental vaccine give intramuscular injection follow electrostimulation cancer patient .</brief_summary>
	<brief_title>V930 First Man ( FIM ) Study ( V930-002 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<criteria>Patients must stag II , III , IV breast , colorectal , ovaria , nonsmall cell lung cancer Patients either disease free follow primary therapy advance disease durable response ( &gt; 3 month ) standard therapy Tumor antigen HER2 and/or CEA must measurable blood detect Immunohistochemistry stain biopsy obtain primary tumor metastasis Patients prior treatment HER2 and/or CEA contain vaccine Patients significant cardiac disease Patients autoimmune disorder Patients pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>